Overview

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or metastatic urothelial cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Mabwell (Shanghai) Bioscience Co., Ltd.